HLB Life Science Co. Ltd Total Liabilities
HLB Life Science Co. Ltd total liabilities. Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has total liabilities worth ₩173.00 Billion KRW (≈ $117.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HLB Life Science Co. Ltd (067630) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HLB Life Science Co. Ltd (2012–2024)
Total liabilities of HLB Life Science Co. Ltd from 2012 to 2024. This chart illustrates how HLB Life Science Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of HLB Life Science Co. Ltd to see how much of total assets are deployed in long-term investments.
HLB Life Science Co. Ltd Competitors by Total Liabilities
The table below lists competitors of HLB Life Science Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asefa Public Company Limited
BK:ASEFA
|
Thailand | ฿2.43 Billion |
|
Jw Life Science Corp
KO:234080
|
Korea | ₩79.02 Billion |
|
SLOMAN NEPTUN Schiffahrts-Aktiengesellschaft
HM:NEP
|
Germany | €94.77 Million |
|
KUB Malaysia Bhd
KLSE:6874
|
Malaysia | RM244.93 Million |
|
K2 Gold Corporation
V:KTO
|
Canada | CA$831.95K |
|
La Française de l'Energie S.A.
PA:FDE
|
France | €158.57 Million |
|
DMS Co.Ltd
KQ:068790
|
Korea | ₩135.93 Billion |
|
Devyser Diagnostics AB
ST:DVYSR
|
Sweden | Skr112.10 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down HLB Life Science Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 067630 asset base.
Liquidity & Leverage Metrics
HLB Life Science Co. Ltd Total Liabilities Ratios Explained
HLB Life Science Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HLB Life Science Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HLB Life Science Co. Ltd (2012–2024)
The table below shows the annual total liabilities of HLB Life Science Co. Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩140.19 Billion ≈ $95.01 Million |
-27.09% |
| 2023-12-31 | ₩192.29 Billion ≈ $130.31 Million |
+8.60% |
| 2022-12-31 | ₩177.07 Billion ≈ $119.99 Million |
+619.47% |
| 2021-12-31 | ₩24.61 Billion ≈ $16.68 Million |
-38.50% |
| 2020-12-31 | ₩40.02 Billion ≈ $27.12 Million |
-43.73% |
| 2019-12-31 | ₩71.11 Billion ≈ $48.19 Million |
-57.46% |
| 2018-12-31 | ₩167.17 Billion ≈ $113.29 Million |
+261.90% |
| 2017-12-31 | ₩46.19 Billion ≈ $31.30 Million |
-16.00% |
| 2016-12-31 | ₩54.99 Billion ≈ $37.27 Million |
+227.27% |
| 2015-12-31 | ₩16.80 Billion ≈ $11.39 Million |
-15.78% |
| 2014-12-31 | ₩19.95 Billion ≈ $13.52 Million |
-46.35% |
| 2013-12-31 | ₩37.19 Billion ≈ $25.20 Million |
-4.21% |
| 2012-12-31 | ₩38.83 Billion ≈ $26.31 Million |
-- |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more